Compare AMTX & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMTX | AGEN |
|---|---|---|
| Founded | 2005 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.4M | 147.4M |
| IPO Year | 2023 | 1999 |
| Metric | AMTX | AGEN |
|---|---|---|
| Price | $1.96 | $3.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $12.00 | ★ $14.50 |
| AVG Volume (30 Days) | ★ 1.1M | 581.5K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 32.98 | ★ 100.00 |
| EPS | N/A | ★ 1.02 |
| Revenue | ★ $77,194,000.00 | $42,877,086.00 |
| Revenue This Year | $49.77 | $107.63 |
| Revenue Next Year | $57.87 | N/A |
| P/E Ratio | ★ N/A | $2.91 |
| Revenue Growth | ★ 174.60 | 89.95 |
| 52 Week Low | $1.30 | $2.71 |
| 52 Week High | $3.80 | $7.34 |
| Indicator | AMTX | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 35.60 | 38.27 |
| Support Level | $1.38 | $2.93 |
| Resistance Level | $2.25 | $3.15 |
| Average True Range (ATR) | 0.16 | 0.22 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 8.63 | 11.19 |
Aemetis Inc is an renewable fuel and biochemicals company focused on the production of renewable fuels and chemicals through the acquisition, development and commercialization of technologies that replace traditional petroleum-based products through the conversion of first-generation ethanol and biodiesel plants into biorefineries. In addition to low carbon renewable fuel ethanol, the Keyes Plant produces Wet Distillers Grains, Distillers Corn Oil, and Condensed Distillers Solubles, all of which are sold to local dairies and feedlots as animal feed. The operations include California Ethanol, California Dairy Renewable Natural Gas and India Biodiesel. It operates in the reportable geographic segments of North America and India.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.